These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8888118)

  • 1. The niacin challenge test in schizophrenia: past, present and future.
    Lin A; Hudson CJ
    Prostaglandins Leukot Essent Fatty Acids; 1996 Aug; 55(1-2):17-9. PubMed ID: 8888118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The niacin challenge test: clinical manifestation of altered transmembrane signal transduction in schizophrenia?
    Hudson CJ; Lin A; Cogan S; Cashman F; Warsh JJ
    Biol Psychiatry; 1997 Mar; 41(5):507-13. PubMed ID: 9046982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin test in schizophrenia and affective illness.
    Rybakowski J; Weterle R
    Biol Psychiatry; 1991 Apr; 29(8):834-6. PubMed ID: 2054456
    [No Abstract]   [Full Text] [Related]  

  • 4. Niacin skin flush test: a research tool for studying schizophrenia.
    Nadalin S; Buretić-Tomljanović A; Rubesa G; Tomljanović D; Gudelj L
    Psychiatr Danub; 2010 Mar; 22(1):14-27. PubMed ID: 20305586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Test-retest stability of the oral niacin test and electrodermal activity in patients with schizophrenia.
    Nilsson BM; Hultman CM; Ekselius L
    Prostaglandins Leukot Essent Fatty Acids; 2009; 81(5-6):367-72. PubMed ID: 19864122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipid membrane abnormalities and reduced niacin skin flush response in schizophrenia.
    Buretić-Tomljanović A; Giacometti J; Nadalin S; Rubesa G; Vulin M; Tomljanović D
    Psychiatr Danub; 2008 Sep; 20(3):372-83. PubMed ID: 18827766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The niacin response biomarker as a schizophrenia endophenotype: A status update.
    Messamore E
    Prostaglandins Leukot Essent Fatty Acids; 2018 Sep; 136():95-97. PubMed ID: 28688777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin-mediated signaling in schizophrenia.
    Smesny S
    Int Rev Neurobiol; 2004; 59():255-71. PubMed ID: 15006491
    [No Abstract]   [Full Text] [Related]  

  • 9. Impaired phospholipid-related signal transduction in advanced Huntington's disease.
    Puri BK
    Exp Physiol; 2001 Sep; 86(5):683-5. PubMed ID: 11571498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endophenotype properties of niacin sensitivity as marker of impaired prostaglandin signalling in schizophrenia.
    Smesny S; Klemm S; Stockebrand M; Grunwald S; Gerhard UJ; Rosburg T; Sauer H; Blanz B
    Prostaglandins Leukot Essent Fatty Acids; 2007 Aug; 77(2):79-85. PubMed ID: 17904833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niacin skin flush is not diagnostic of schizophrenia.
    Wilson DW; Douglass AB
    Biol Psychiatry; 1986 Aug; 21(10):974-7. PubMed ID: 3741914
    [No Abstract]   [Full Text] [Related]  

  • 12. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations.
    Tessier C; Sweers K; Frajerman A; Bergaoui H; Ferreri F; Delva C; Lapidus N; Lamaziere A; Roiser JP; De Hert M; Nuss P
    Transl Psychiatry; 2016 Oct; 6(10):e906. PubMed ID: 27701405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The niacin skin flush test in schizophrenia: a replication study.
    Puri BK; Easton T; Das I; Kidane L; Richardson AJ
    Int J Clin Pract; 2001; 55(6):368-70. PubMed ID: 11501224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin subsensitivity is associated with functional impairment in schizophrenia.
    Messamore E
    Schizophr Res; 2012 May; 137(1-3):180-4. PubMed ID: 22445461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
    Lai E; De Lepeleire I; Crumley TM; Liu F; Wenning LA; Michiels N; Vets E; O'Neill G; Wagner JA; Gottesdiener K
    Clin Pharmacol Ther; 2007 Jun; 81(6):849-57. PubMed ID: 17392721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical subtyping reveals significant differences in calcium-dependent phospholipase A2 activity in schizophrenia.
    Hudson C; Gotowiec A; Seeman M; Warsh J; Ross BM
    Biol Psychiatry; 1999 Aug; 46(3):401-5. PubMed ID: 10435206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin skin flush in schizophrenia: a preliminary report.
    Ward PE; Sutherland J; Glen EM; Glen AI
    Schizophr Res; 1998 Feb; 29(3):269-74. PubMed ID: 9516668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The membrane hypothesis of schizophrenia.
    Horrobin DF; Glen AI; Vaddadi K
    Schizophr Res; 1994 Oct; 13(3):195-207. PubMed ID: 7841132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipid abnormalities in schizophrenia--current knowledge].
    Michalak G
    Psychiatr Pol; 2003; 37(6):965-76. PubMed ID: 14727369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of age and gender on niacin skin test results - implications for the use as a biochemical marker in schizophrenia.
    Smesny S; Rosburg T; Klemm S; Riemann S; Baur K; Rudolph N; Grunwald S; Sauer H
    J Psychiatr Res; 2004; 38(5):537-43. PubMed ID: 15380405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.